Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials by Bell Daphne W, Lynch Thomas J, Haserlat Sara M, Harris Patricia L, Okimoto Ross A, Brannigan Brian W, Sgroi Dennis C, Muir Beth, Riemenschneider Markus J, Iacona Renee Bailey, Krebs Annetta D, Johnson David H, Giaccone Giuseppe, Herbst Roy S, Manegold Christian, Fukuoka Masahiro, Kris Mark G, Baselga José, Ochs Judith S, Haber Daniel A in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2005).

[PMID: 16204011] PubMed


Most cases of non-small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but the predictive value of these mutations has not been defined in large clinical trials. The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.